End-of-day quote
Shanghai S.E.
06:00:00 2024-05-07 pm EDT
|
5-day change
|
1st Jan Change
|
68.65
CNY
|
-2.25%
|
|
+0.54%
|
-8.63%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
87,383
|
134,459
|
114,799
|
95,280
|
87,062
|
-
|
-
|
Enterprise Value (EV)
1 |
87,383
|
134,459
|
114,799
|
91,759
|
81,793
|
81,809
|
80,400
|
P/E ratio
|
124
x
|
66.5
x
|
23.9
x
|
75.9
x
|
38.9
x
|
28.4
x
|
22.2
x
|
Yield
|
-
|
0.09%
|
0.79%
|
0.43%
|
0.21%
|
0.27%
|
0.38%
|
Capitalization / Revenue
|
37.1
x
|
23.4
x
|
10.3
x
|
17.3
x
|
18
x
|
12
x
|
6.03
x
|
EV / Revenue
|
37.1
x
|
23.4
x
|
10.3
x
|
16.7
x
|
16.9
x
|
11.3
x
|
5.57
x
|
EV / EBITDA
|
101
x
|
55.3
x
|
20
x
|
55.9
x
|
40.4
x
|
25
x
|
11.3
x
|
EV / FCF
|
1,085,446,252
x
|
209,323,356
x
|
35,834,780
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
0%
|
0%
|
0%
|
-
|
-
|
-
|
-
|
Price to Book
|
34.2
x
|
30.1
x
|
9.3
x
|
7.5
x
|
6.26
x
|
4.99
x
|
3.82
x
|
Nbr of stocks (in thousands)
|
1,232,291
|
1,232,291
|
1,268,499
|
1,268,207
|
1,268,207
|
-
|
-
|
Reference price
2 |
70.91
|
109.1
|
90.50
|
75.13
|
68.65
|
68.65
|
68.65
|
Announcement Date
|
3/4/21
|
2/14/22
|
1/19/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
2,354
|
5,750
|
11,185
|
5,511
|
4,844
|
7,226
|
14,431
|
EBITDA
1 |
861.7
|
2,430
|
5,739
|
1,641
|
2,026
|
3,274
|
7,099
|
EBIT
1 |
775.2
|
2,328
|
5,596
|
1,401
|
1,833
|
4,216
|
6,438
|
Operating Margin
|
32.93%
|
40.49%
|
50.03%
|
25.43%
|
37.84%
|
58.35%
|
44.61%
|
Earnings before Tax (EBT)
1 |
764.5
|
2,324
|
5,583
|
1,393
|
1,642
|
2,785
|
6,488
|
Net income
1 |
677
|
2,021
|
4,736
|
1,248
|
2,553
|
3,466
|
5,552
|
Net margin
|
28.76%
|
35.15%
|
42.34%
|
22.64%
|
52.69%
|
47.96%
|
38.48%
|
EPS
2 |
0.5700
|
1.640
|
3.793
|
0.9900
|
1.765
|
2.415
|
3.094
|
Free Cash Flow
|
80.5
|
642.4
|
3,204
|
-
|
-
|
-
|
-
|
FCF margin
|
3.42%
|
11.17%
|
28.64%
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
9.34%
|
26.44%
|
55.82%
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
11.89%
|
31.78%
|
67.65%
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
0.0985
|
0.7143
|
0.3200
|
0.1474
|
0.1881
|
0.2627
|
Announcement Date
|
3/4/21
|
2/14/22
|
1/19/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
1,277
|
805.3
|
541.9
|
1,115
|
1,115
|
1,204
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
425
|
-42.27
|
-603.5
|
460.2
|
458.2
|
547.4
|
-
|
-
|
Operating Margin
|
33.28%
|
-5.25%
|
-111.36%
|
41.29%
|
41.11%
|
45.47%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
501.2
|
68.11
|
-609.4
|
472.7
|
470.7
|
559.9
|
-
|
-
|
Net income
1 |
457.4
|
106
|
-560.7
|
404.9
|
402.9
|
492
|
-
|
-
|
Net margin
|
35.82%
|
13.16%
|
-103.47%
|
36.32%
|
36.14%
|
40.87%
|
-
|
-
|
EPS
2 |
0.3600
|
0.0900
|
-0.4400
|
0.3192
|
0.3177
|
0.3880
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
0.0191
|
0.0191
|
0.0191
|
0.0432
|
0.0432
|
Announcement Date
|
8/24/23
|
10/27/23
|
3/28/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
3,521
|
5,270
|
5,253
|
6,663
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
80.5
|
642
|
3,204
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
35.7%
|
54%
|
56.2%
|
9.97%
|
10.6%
|
23.3%
|
27.6%
|
ROA (Net income/ Total Assets)
|
23.9%
|
-
|
40.7%
|
7.81%
|
-
|
-
|
-
|
Assets
1 |
2,834
|
-
|
11,638
|
15,972
|
-
|
-
|
-
|
Book Value Per Share
2 |
2.070
|
3.620
|
9.730
|
10.00
|
11.00
|
13.80
|
18.00
|
Cash Flow per Share
|
0.3800
|
1.360
|
3.260
|
1.210
|
-
|
-
|
-
|
Capex
1 |
388
|
1,040
|
929
|
1,159
|
446
|
853
|
1,299
|
Capex / Sales
|
16.47%
|
18.08%
|
8.31%
|
21.03%
|
9.2%
|
11.81%
|
9%
|
Announcement Date
|
3/4/21
|
2/14/22
|
1/19/23
|
3/28/24
|
-
|
-
|
-
|
Last Close Price
68.65
CNY Average target price
70.4
CNY Spread / Average Target +2.55% Consensus |
1st Jan change
|
Capi.
|
---|
| -8.63% | 12.05B | | -3.35% | 88.91B | | +4.08% | 41.25B | | -15.09% | 31.99B | | +52.22% | 24.73B | | -15.13% | 15.54B | | -40.39% | 12.07B | | +6.22% | 8.84B | | -5.50% | 8.3B | | -6.45% | 7.07B |
Biopharmaceuticals
|